Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Lucentis TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: ranibizumab
Brand name
(ARTG)
: LUCENTIS ranibizumab (rbe) 2.3 mg/0.23 mL solution for injection vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Lucentis (ranibizumab) is indicated in adults for:, the treatment of neovascular (wet) age-related macular degeneration (AMD), the treatment of visual impairment due to diabetic macular oedema (DME), treatment of proliferative diabetic retinopathy (PDR), the treatment of visual impairment due to choroidal neovascularisation, the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).,Lucentis is indicated in preterm infants for:, the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intravitreal-Within The Vitreous Cavity Of The Eye
- Clear, colourless to pale yellow solution
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Protect from Light
- Do not Freeze
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 x vial pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on January, 1 2025. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient ranibizumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.